T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions
نویسندگان
چکیده
Several key advances in the treatment of B-cell non-Hodgkin lymphoma (B-NHL) over past two decades have strategically exploited lineage markers suitable for targeting by immunotherapies. First, addition anti-CD20 monoclonal antibody (mAb) rituximab to a range standard therapies conferred remarkable outcomes improvements diverse settings, perhaps most prominently an overall survival advantage newly diagnosed diffuse large (DLBCL). Subsequently, multiple chimeric antigen receptor (CAR) T-cell CD19 revolutionized relapsed/refractory (rel/ref) DLBCL and are active other B-NHL subtypes as well. Most recently, longstanding aspiration exploit patients’ endogenous T-cells combat has been achieved via redirecting such bispecific antibodies (BsAbs) that incorporate dual CD3 plus or CD20 expressed tumor. These novel agents demonstrated impressive activity monotherapies patients with heavily pre-treated, rel/ref variety subtypes. Now, myriad clinical trials exploring combinations redirectors targeted therapies, antibody-drug conjugates, conventional chemotherapy, even new Here, we highlight landmarks development B-NHL, emerging evidence lessons from recent trials, exciting directions this arena.
منابع مشابه
T-cell non-Hodgkin lymphoma.
T-cell non-Hodgkin lymphomas (NHLs) are uncommon malignancies. The current WHO/EORTC classification recognizes 9 distinct clinicopathologic peripheral T-cell NHLs. These disorders have unique characteristics and require individualized diagnostic and therapeutic strategies. Tremendous progress has been made in recent years in the understanding of the pathogenesis of these disorders. Specific chr...
متن کاملUnusual Presentation of T-cell non-Hodgkin Lymphoma with Multiple Skin Nodules
Non-Hodgkin lymphoma is very uncommon in infancy and skin as the primary site of involvement in Non-Hodgkin lymphoma is rarely encountered. We describe a 10-month-old infant with T-cell Non-Hodgkin lymphoma who presented with multiple skin nodules as the predominant feature of her disease. The clinical manifestations, treatment strategy and disease outcome are reviewed. Key words: Non-Hodgk...
متن کاملDendritic cell vaccine treatment for indolent B cell non-hodgkin lymphoma: clinical trial in progress
Methods Autologous mature dendritic cells (mDC) were manufactured from leukapheresed cells of NHL patients. For patients with tumor lymph nodes deemed amenable to cryoablation by interventional radiologist (arm A), they received cryoablation of a node and injection of mDC into the cryoablated node followed by another 1 to 7 intratumoral mDC injections. Remaining patients had a tumor excised to ...
متن کاملEmploying PCR Technique in Assessment of Monoclonality in Large B-cell Non-Hodgkin\'s Lymphoma
Introduction: Most B-cell malignancies are diagnosed based on morphologic and immunohistochemical criteria. Some cases, however, still present a challenge for the pathologist to discriminate between reactive hyperplasia and neoplastic disorders. Molecular techniques can be used as a helpful diagnostic tool in these cases. In this study, we assessed the value of polymerase chain reaction (PCR) t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Oncology
سال: 2023
ISSN: ['2234-943X']
DOI: https://doi.org/10.3389/fonc.2023.1168622